CureVac (NASDAQ:CVAC) Sees Strong Trading Volume

CureVac (NASDAQ:CVACGet Free Report) saw strong trading volume on Thursday . 975,123 shares traded hands during mid-day trading, a decline of 0% from the previous session’s volume of 975,509 shares.The stock last traded at $4.95 and had previously closed at $4.53.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on the stock. SVB Leerink lowered shares of CureVac from an “outperform” rating to a “market perform” rating and dropped their price objective for the company from $12.00 to $4.00 in a report on Thursday, April 25th. Leerink Partnrs lowered shares of CureVac from an “outperform” rating to a “market perform” rating in a report on Thursday, April 25th. Finally, Guggenheim reissued a “neutral” rating on shares of CureVac in a report on Friday, April 5th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and one has assigned a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $8.33.

Get Our Latest Stock Analysis on CureVac

CureVac Trading Down 10.0 %

The company has a debt-to-equity ratio of 0.08, a current ratio of 2.25 and a quick ratio of 2.09. The company has a market cap of $1.01 billion, a PE ratio of -3.38 and a beta of 2.68. The company’s 50 day simple moving average is $3.17 and its two-hundred day simple moving average is $3.71.

CureVac (NASDAQ:CVACGet Free Report) last announced its earnings results on Wednesday, April 24th. The company reported ($0.42) earnings per share for the quarter. The company had revenue of $24.30 million for the quarter. CureVac had a negative return on equity of 49.22% and a negative net margin of 463.49%. As a group, sell-side analysts anticipate that CureVac will post -1.11 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. Optiver Holding B.V. boosted its stake in shares of CureVac by 2,407.0% in the third quarter. Optiver Holding B.V. now owns 6,844 shares of the company’s stock valued at $47,000 after purchasing an additional 6,571 shares during the period. Vontobel Holding Ltd. acquired a new stake in CureVac in the fourth quarter valued at approximately $45,000. Ballentine Partners LLC acquired a new stake in CureVac in the first quarter valued at approximately $38,000. Pathstone Family Office LLC acquired a new stake in CureVac in the third quarter valued at approximately $89,000. Finally, Vanguard Personalized Indexing Management LLC acquired a new stake in CureVac in the fourth quarter valued at approximately $68,000. Hedge funds and other institutional investors own 17.26% of the company’s stock.

CureVac Company Profile

(Get Free Report)

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.

See Also

Receive News & Ratings for CureVac Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CureVac and related companies with MarketBeat.com's FREE daily email newsletter.